Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Michelle Head

Nurse Practitioner, Psychiatric/Mental Health Little Rock, AR Nurse Practitioner

NPI 1568929826 CMS profile 10841644

10025 W Markham St Ste 210, Little Rock, AR 72205

Open in the dashboard

General payments

$6,225

312 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Michelle Head of Little Rock, AR is reported in the CMS Open Payments database as having received $6,225 across 312 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Nurse Practitioner, Psychiatric/Mental Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $674 35
2024 General $1,865 69
2023 General $2,087 112
2022 General $974 60
2021 General $625 36

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michelle Head
  • Nurse Practitioner, Psychiatric/Mental Health median
  • Middle half of Nurse Practitioner, Psychiatric/Mental Health
  • National median

In program year 2025, general payments to Michelle Head were reported at $674. Among 26,152 Nurse Practitioner, Psychiatric/Mental Health profiles paid that year, the median was $258 and the middle half received between $93 and $764.

Show as a table
Year Michelle Head Nurse Practitioner, Psychiatric/Mental Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $625 $166 $54–$482 $132
2022 $974 $195 $66–$559 $149
2023 $2,087 $233 $82–$673 $160
2024 $1,865 $236 $84–$688 $164
2025 $674 $258 $93–$764 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,018 87 payments
  2. Janssen Pharmaceuticals, Inc $749 34 payments
  3. Otsuka America Pharmaceutical, Inc. $716 32 payments
  4. Teva Pharmaceuticals USA, Inc. $708 26 payments
  5. Neuronetics, Inc. $583 6 payments
  6. Axsome Therapeutics, Inc. $413 20 payments
  7. Alkermes, Inc. $407 20 payments
  8. ITI, Inc. $337 17 payments
  9. Neurocrine Biosciences, Inc. $315 17 payments
  10. Takeda Pharmaceuticals U.S.A., Inc. $276 19 payments
  11. Other $702 34 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $6,225 312 payments
Products named General payments · program years 2021–2025
  1. VRAYLAR $823 73 payments
  2. REXULTI $702 31 payments
  3. SPRAVATO $583 27 payments
  4. Neurostar TMS Therapy System $583 6 payments
  5. Austedo XR $467 11 payments
  6. Auvelity $380 18 payments
  7. CAPLYTA $337 17 payments
  8. LYBALVI $322 16 payments
  9. INGREZZA $298 16 payments
  10. TRINTELLIX $276 19 payments
  11. Other $3,042 156 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 33 drugs

Part D claims

1,219

Median for Nurse Practitioner: 389

Drug cost

$102,180

Median for Nurse Practitioner: $21,885

Branded share of claims

19.4%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Spravato Esketamine Hcl Brand 39 $47,418
Vraylar Cariprazine Hcl Brand 13 $18,131
Lybalvi Olanzapine/Samidorphan Malate Brand 11 $17,685
Lurasidone Hcl Generic 15 $4,816
Ramelteon Generic 21 $1,990
Duloxetine Hcl Generic 93 $1,496
Aripiprazole Generic 72 $1,296
Bupropion Xl Bupropion Hcl Brand 60 $1,133
Desvenlafaxine Succinate Er Desvenlafaxine Succinate Brand 34 $946
Trazodone Hcl Generic 119 $795

The 10 drugs with the highest cost, of 33 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 7 billing codes

Paid by Medicare

$12,816

Medicare's payments for the services billed

Medicare patients

49

Average age 63

Services billed

233

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Depression 75%
High blood pressure 61%
Arthritis 59%
Diabetes 27%
Ischemic heart disease 27%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 17 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $273
$273 13 —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $183
  • Lundbeck LLC $24
$207 — —
COBENFY
  • E.R. Squibb & Sons, L.L.C. $144
$144 — —
Auvelity
  • Axsome Therapeutics, Inc. $132
$132 — —
CAPLYTA
  • ITI, Inc. $113
$113 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 17 in the dashboard with a free account

Records

312 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Psychiatric/Mental Health in Arkansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record